Abstract

Meclofenoxate (Lucidril), synthesised in 1959,¹ has been used in clinical practice for 8 years. When we reviewed it in 1964,² few of the clinical and pharmacological studies stood up to critical examination and we thought it had been marketed prematurely. The manufacturers continue to suggest its use in several conditions in which there is ‘cerebral dysfunction’, and particularly in patients with intellectual impairment in old age or following strokes.